Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong,
Inflammation. 2015 Feb;38(1):348-60. doi: 10.1007/s10753-014-0038-4.
We investigated the plasma concentration of the novel regulatory cytokine IL-35 and intracytosolic pattern recognition receptors nucleotide-binding oligomerization domain (NOD)-like receptors in granulocytes and explored their potential implication in disease severity monitoring of allergic asthma. The expression of circulating IL-35 and other pro-inflammatory mediators in asthmatic patients or control subjects were evaluated using enzyme-linked immunosorbent assay (ELISA). The intracellular expressions of NOD1 and NOD2 in CCR3+ granulocytes were assessed using flow cytometry. Plasma concentrations of IL-35, IL-17A, basophil activation marker basogranulin, and eosinophilic airway inflammation biomarker periostin were significantly elevated in allergic asthmatic patients compared to non-atopic control subjects (all probability (p) <0.05). Both granulocyte markers exhibited significant and positive correlation with plasma IL-35 concentration in asthmatic patients (all p < 0.05). Significant positive correlation was also identified between plasma concentrations of IL-35 and periostin with disease severity score in asthmatic patients (both p < 0.05). The basophil activation allergenicity test was positive in allergic asthmatic patients but not in control subjects. Despite significantly elevated eosinophil count in allergic asthmatic patients, downregulation of NOD2 in CCR3+ granulocytes was observed in these patients (both p < 0.05). A negative correlation between plasma concentrations of tumor necrosis factor family member LIGHT and soluble herpesvirus entry mediator was observed in patients with elevated plasma concentration of IL-35 (p < 0.05). Aberrant expression of NOD2 in granulocytes may be contributed to the impaired innate immunity predisposing allergic asthma. IL-35 may serve as a potential surrogate biomarker for disease severity of allergic asthma.
我们研究了新型调节细胞因子白细胞介素-35(IL-35)和细胞内模式识别受体核苷酸结合寡聚结构域(NOD)样受体在粒细胞中的血浆浓度,并探讨了它们在过敏性哮喘疾病严重程度监测中的潜在意义。采用酶联免疫吸附试验(ELISA)评估哮喘患者和对照受试者循环中的 IL-35 和其他促炎介质的表达。采用流式细胞术评估 CCR3+粒细胞中 NOD1 和 NOD2 的细胞内表达。与非特应性对照受试者相比,过敏性哮喘患者的血浆 IL-35、IL-17A、嗜碱性粒细胞激活标志物 basogranulin 和嗜酸性气道炎症生物标志物 periostin 浓度明显升高(所有概率(p)<0.05)。在哮喘患者中,两种粒细胞标志物与血浆 IL-35 浓度均呈显著正相关(所有 p<0.05)。IL-35 和 periostin 与哮喘患者疾病严重程度评分之间也存在显著正相关(均 p<0.05)。过敏性哮喘患者的嗜碱性粒细胞激活变应原性试验阳性,但对照受试者未阳性。尽管过敏性哮喘患者的嗜酸性粒细胞计数明显升高,但在这些患者中观察到 CCR3+粒细胞中 NOD2 的下调(均 p<0.05)。在血浆 IL-35 浓度升高的患者中,观察到肿瘤坏死因子家族成员 LIGHT 和可溶性疱疹病毒进入介质之间的负相关(p<0.05)。粒细胞中 NOD2 的异常表达可能导致过敏性哮喘中先天免疫受损。IL-35 可能作为过敏性哮喘疾病严重程度的潜在替代生物标志物。